A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to demonstrate the clinical efficacy of abatacept (body-weight
tiered dose approximating 10 mg/kg) compared with placebo on a background of methotrexate
after 6 months (Day 169) of treatment in Korean patients with active rheumatoid arthritis and
an inadequate clinical response to methotrexate